Hailey-Hailey Disease (Benign Familial Pemphigus)

Clinical guidelines for managing inherited blistering disorders, evaluating ATP2C1 mutations and Golgi calcium dysregulation, and reviewing low-dose Naltrexone parameters.

⏱️ 4 min read

Table of Contents

🧠 Standard of Care & Symptoms

Hailey-Hailey Disease (HHD), also known as benign familial pemphigus, is a rare, autosomal dominant genetic blistering disorder that primarily targets friction-prone skin folds.

🧬 Diagnostics & ATP2C1 Golgi Calcium Pathology

Diagnosis is suspected based on recurrent intertriginous rashes with a family history, and confirmed by skin biopsy and molecular testing.

Pathogenesis & SPCA1 Golgi Ca2+ Depletion

The loss of cell adhesion in HHD is driven by abnormal calcium concentrations inside cellular organelles:

πŸ’Š Friction Control & Low-Dose Naltrexone

Management focuses on reducing local friction and sweating, treating secondary infections, and utilizing systemic calcium-modulating drugs.

Friction and Sweat Reduction

Pharmacological Management

πŸ”¬ Active Clinical Trials

Clinical trials are currently evaluating low-dose naltrexone in large patient cohorts, topical calcium channel blockers designed to normalize skin calcium levels, and local laser ablation protocols.

NCT06922755: Low-Dose Naltrexone (LDN) in Hailey-Hailey Disease

A randomized, double-blind Phase II trial evaluating whether daily oral LDN (3.0 mg) reduces the severity and frequency of intertriginous flares.

Key Inclusion: Age ≥ 18, biopsy-confirmed HHD, and at least two active intertriginous plaques at screening.
NCT07050559: Topical Calcium Modulator (Carisbamate) Gel

Testing whether a topical gel designed to regulate intracellular calcium levels restores desmosome synthesis and improves skin barrier integrity.

Key Inclusion: Age ≥ 18, diagnosed with HHD, and willing to wash off other topical treatments.
NCT07119555: Botulinum Toxin Type A for Inguinal Hailey-Hailey

Evaluating the duration of flare prevention following localized intradermal injections of Botox in the groin folds.

Key Inclusion: Age ≥ 18, active bilateral inguinal HHD, and history of sweat-triggered flares.
Important: Browse actively recruiting clinical trials in our Clinical Trials Catalogue to find a local study.

πŸ—ΊοΈ Next Steps After Diagnosis

If you have recently been diagnosed with Hailey-Hailey Disease, coordinate these care steps:

  1. Review Histology Report: Ensure your skin biopsy shows the pathognomonic "dilapidated brick wall" pattern to rule out autoimmune pemphigus.
  2. Order genetic screening for ATP2C1 mutations: Confirm the diagnosis and assist in family planning.
  3. Discuss low-dose Naltrexone (LDN): Ask your dermatologist about starting a low-dose trial of oral Naltrexone (usually 1.5 - 4.5 mg) to stabilize calcium levels.
  4. Implement Sweat and Friction Control: Wear loose cotton clothing, manage weight, and use antibacterial soaps (like Chlorhexidine) to prevent smelly secondary infections.

❓ Patient FAQ

Q: Is Hailey-Hailey disease related to autoimmune pemphigus?
A: No. While both diseases cause painful skin blisters and peeling (acantholysis), their causes are entirely different. Autoimmune pemphigus is caused by your immune system producing rogue antibodies that attack the skin's glue. Hailey-Hailey disease is an inherited genetic condition caused by a mutation in the **ATP2C1** gene, which impairs the skin cells' ability to pump calcium and manufacture desmosomes properly. Direct immunofluorescence tests are negative in Hailey-Hailey disease.

Q: Why does my skin smell so bad when I have a flare?
A: The genetic mutation in Hailey-Hailey disease prevents your skin cells from sticking together properly, leaving raw, open sores in warm, moist areas like the armpits and groin. These environments are ideal for bacteria (like Staphylococcus) and yeast (like Candida) to multiply. When they colonize the raw, weeping skin plaques, they break down skin proteins, producing a characteristic, strong odor (malodor). This is managed with antiseptic washes and topical antibiotics.

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email